Latest Breaking News On - நிறுவனம் கியூரி - Page 7 : comparemela.com

EGFR inhibitor-resistant non-small cell lung cancer (NSCLC), a preliminary clinical trial showed. Patritumab deruxtecan (HER3-DXd) led to objective responses in 22 of 57 patients and stable disease in 19 others. Results were almost identical in a subgroup of patients previously treated with osimertinib (Tagrisso) and platinum-based chemotherapy. A third of patients with brain metastases responded to the drug. Responses occurred across a diverse range of resistance mechanisms, reported Pasi Jänne, MD, PhD, of Dana Farber Cancer Institute in Boston, at the American Society of Clinical Oncology (ASCO) virtual meeting. HER3-DXd led to clinically meaningful and durable efficacy across a range of EGFR TKI [tyrosine kinase inhibitor] mechanisms in this population of patients that is often difficult to treat and with diverse resistance mechanisms or where you don t have a resistance mechanism, said Jänne. Antitumor activity was observed across a wide range of baseline HER3 expression

United statesDana farber cancer instituteFrance generalCharles bankheadNicolas girardInstitut curieAmerican society of clinical oncologyAmerican societyClinical oncologyMedpage todayஒன்றுபட்டது மாநிலங்களில்டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம்பிரான்ஸ் ஜநரல்சார்லஸ் வங்கித் தலைநிக்கோலாஸ் ஜிரார்ட்நிறுவனம் கியூரி